Later on, due to the JAK-STAT pathway’s role in SARS-CoV-2-induced dysregulated hyper-immunity, inflammation, and fibrosis, Jakinibs have gained impetus to be repurposed as COVID-19 patient treatment due to their anti-inflammatory and immunomodulatory activity (Montero et al., 2021). This evidence concerns the gene SOAT1 and COVID-19.